Loading institutional data...
Loading institutional data...
Held by 375 of 5,944 reporting institutions (96th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 6%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $446M covers all $328M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2016-09-30 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~3.6% on $734M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $85.57 today, the market must believe free cash flow compounds 13.9%/yr for a decade (off $171M normalized FCF).
The market's 13.9% is more conservative than its 9-yr track record.
2-stage DCF · 0.06B shares · net debt $288M
mean 1.6% · volatility σ 54% · implied rate exceeded in 4/8 yrs
Central path = implied 13.9%/yr growth; shaded band = ±1σ (54%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $216M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.52B 100.0% | $1.36B 100.0% | $1.26B 100.0% | $1.15B 100.0% | $1.07B 100.0% | $963.9M 100.0% | $994.9M 100.0% | $882.8M 100.0% | $727.9M 100.0% | $603.8M 100.0% |
| Cost of Revenue | $777.6M 51.3% | $713.2M 52.6% | $673.5M 53.6% | $631.9M 54.9% | $589.4M 54.8% | $562.7M 58.4% | $562.5M 56.5% | $488.0M 55.3% | $401.6M 55.2% | $338.8M 56.1% |
| Cost of Products | — | — | — | — | — | — | — | — | $401.6M 55.2% | $338.8M 56.1% |
| Gross Profit | $738.3M 48.7% | $643.3M 47.4% | $583.9M 46.4% | $519.1M 45.1% | $485.3M 45.2% | $401.2M 41.6% | $432.4M 43.5% | $394.8M 44.7% | $326.3M 44.8% | $265.0M 43.9% |
| Research & Development | — | — | — | — | — | — | — | $59.5M 6.7% | $51.4M 7.1% | $45.2M 7.5% |
| Selling, General & Admin | $455.2M 30.0% | $399.7M 29.5% | $373.7M 29.7% | $342.5M 29.8% | $335.7M 31.2% | $297.7M 30.9% | $327.3M 32.9% | $276.0M 31.3% | $229.1M 31.5% | $184.4M 30.5% |
| Total Operating Expenses | $553.5M 36.5% | $487.6M 35.9% | $459.9M 36.6% | $431.5M 37.5% | $424.4M 39.5% | $402.7M 41.8% | $416.9M 41.9% | $336.2M 38.1% | $293.2M 40.3% | $230.1M 38.1% |
| Operating Income | $184.7M 12.2% | $155.7M 11.5% | $123.9M 9.9% | $87.6M 7.6% | $60.9M 5.7% | -$1.6M -0.2% | $15.4M 1.6% | $58.6M 6.6% | $33.1M 4.5% | $34.9M 5.8% |
| Interest Expense | $26.5M 1.7% | $31.2M 2.3% | $15.5M 1.2% | $6.3M 0.6% | $5.3M 0.5% | $10.0M 1.0% | $12.4M 1.2% | $10.4M 1.2% | $7.7M 1.1% | $8.8M 1.5% |
| Interest & Investment Income | — | — | — | — | — | — | — | $1.2M 0.1% | $381K 0.1% | $81K 0.0% |
| Other Income (Expense), net | -$13.8M -0.9% | -$5.7M -0.4% | -$11.9M -0.9% | -$4.9M -0.4% | -$7.0M -0.7% | -$11.7M -1.2% | -$13.2M -1.3% | -$9.1M -1.0% | $2.8M 0.4% | -$9.5M -1.6% |
| Pretax Income | $170.9M 11.3% | $150.0M 11.1% | $112.1M 8.9% | $82.6M 7.2% | $53.9M 5.0% | -$13.2M -1.4% | $2.2M 0.2% | $49.5M 5.6% | $35.9M 4.9% | $25.4M 4.2% |
| Income Tax Expense | $42.4M 2.8% | $29.6M 2.2% | $17.7M 1.4% | $8.1M 0.7% | $5.5M 0.5% | -$3.4M -0.4% | -$3.3M -0.3% | $7.5M 0.8% | $8.4M 1.1% | $5.3M 0.9% |
| Net Income | $128.5M 8.5% | $120.4M 8.9% | $94.4M 7.5% | $74.5M 6.5% | $48.5M 4.5% | -$9.8M -1.0% | $5.5M 0.5% | $42.0M 4.8% | $27.5M 3.8% | $20.1M 3.3% |
| Per Share | ||||||||||
| EPS (Basic) | $2.17 | $2.07 | $1.64 | $1.31 | $0.86 | $-0.18 | $0.10 | $0.80 | $0.56 | $0.45 |
| EPS (Diluted) | $2.13 | $2.03 | $1.62 | $1.29 | $0.84 | $-0.18 | $0.10 | $0.78 | $0.55 | $0.45 |
| Weighted Avg Shares (Basic) | 59.2M | 58.2M | 57.6M | 56.8M | 56.1M | 55.4M | 55.1M | 52.3M | 48.8M | 44.4M |
| Weighted Avg Shares (Diluted) | 60.5M | 59.4M | 58.4M | 57.7M | 57.4M | 55.4M | 56.2M | 53.9M | 50.1M | 44.9M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 42th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.6× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 55.3 | 56.5 | 58.4 | 54.8 | 54.9 | 53.6 | 52.6 | 51.3 |
| Gross Profit | 44.7 | 43.5 | 41.6 | 45.2 | 45.1 | 46.4 | 47.4 | 48.7 |
| R&D | 6.7 | — | — | — | — | — | — | — |
| SG&A | 31.3 | 32.9 | 30.9 | 31.2 | 29.8 | 29.7 | 29.5 | 30.0 |
| Operating Income | 6.6 | 1.6 | -0.2 | 5.7 | 7.6 | 9.9 | 11.5 | 12.2 |
| Income Tax | 0.8 | -0.3 | -0.4 | 0.5 | 0.7 | 1.4 | 2.2 | 2.8 |
| Net Income | 4.8 | 0.5 | -1.0 | 4.5 | 6.5 | 7.5 | 8.9 | 8.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on MMSI: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| MMSI | $5.1B | 40.2× | 17.4× | 3.4× | 11.8% | 48.7% | 8.5% | 8.1% | 5.5% | 2.4× | 375 |
Peers = companies sharing MMSI's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.